Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling


N/A
18 Years
N/A
Not Enrolling
Both
Hematologic Malignancies

Thank you

Trial Information

Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling


Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and
differences between normal and leukemic cells in patients with hematologic malignancy prior
to and following treatment.

Inclusion Criteria


Histologic proof of one of:

- AML, ALL, or AUL

- MDS or CMML

- CML

- OR undergoing bone marrow transplantation.

Participants should be:

- off therapy for at least two weeks

- At least 18 years old or older

- Using adequate contraception if of child-bearing capability.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Principal Investigator

Michael Andreeff, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

M.D. Anderson Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

DM91-102

NCT ID:

NCT00042250

Start Date:

May 1992

Completion Date:

October 2002

Related Keywords:

  • Hematologic Malignancies
  • Cell Cycle Interphase
  • G0
  • G1
  • G2
  • S Phase
  • Neoplasms
  • Hematologic Neoplasms

Name

Location
M.D. Anderson Cancer Center Houston, Texas  77030